ReviewBioanalysis2013
Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy.
Review in Bioanalysis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment.Discover nano · 2025Review
- Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research.Antibody therapeutics · 2025Review
- Photodynamic Therapy as a Desirable Approach in the Treatment of Colorectal Cancer, with Special Focus on Photodynamic Nanotherapeutics in Immunotherapy.Current medicinal chemistry · 2025Review
- Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics.Cancers · 2023Review
- Folate receptor-targeted near-infrared photodynamic therapy for folate receptor-overexpressing tumors.World journal of clinical oncology · 2022Article
- EGFR-Targeted Photodynamic Therapy.Pharmaceutics · 2022Review
- Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine.Cancers · 2020Review
- Autophagy Regulation and Photodynamic Therapy: Insights to Improve Outcomes of Cancer Treatment.Frontiers in oncology · 2020Review
- Adjuvant Biophysical Therapies in Osteosarcoma.Cancers · 2019Review
- The Efficacy of Photodynamic Inactivation of the Diode Laser in Inactivation of theJournal of lasers in medical sciences · 2019Article
- Utilisation of Targeted Nanoparticle Photosensitiser Drug Delivery Systems for the Enhancement of Photodynamic Therapy.Molecules (Basel, Switzerland) · 2018Review
- A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.Oncotarget · 2017Review
- Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.Cancers · 2017Review
- Evaluation of oxygen dependence on in vitro and in vivo cytotoxicity of photoimmunotherapy using IR-700-antibody conjugates.Free radical biology & medicine · 2015Article
- Photodynamic therapy: current status and future directions.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2015Review
- Apoptosis of HeLa cells induced by a new targeting photosensitizer-based PDT via a mitochondrial pathway and ER stress.OncoTargets and therapy · 2015Article
- Functionalized fullerenes in photodynamic therapy.Journal of biomedical nanotechnology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Photodynamic therapy (PDT) was discovered in 1900 by Raab, and has since emerged as a promising tool for treating diseases characterized by unwanted cells or hyperproliferating tissue (e.g., cancer or infectious disease). PDT consists of the light excitation of a photosensitizer (PS) in the presence of O(2) to yield highly reactive oxygen species. In recent years, PDT has been improved by the synthesis of targeted bioconjugates between monoclonal antibodies and PS, and by investigating PS biodistribution and PD. Here, we provide a comprehensive review of major developments in PS-immunoconjugate-based PDT and the bioanalysis of these agents, with a specific emphasis on anticancer and antimicrobial PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.